生物基因开始第3阶段研究新肾病药物Felzartamab,目标是罕见的PMN。 Biogen begins Phase 3 study for new kidney disease drug, felzartamab, targeting rare PMN.

生物基因已开始了第3阶段的Prominente研究,以测试一种新药物Felzartamab,用于初级中子肾病(PMN),这是一种罕见的肾病,影响约36 000名美国病人。 Biogen has started a Phase 3 study, PROMINENT, to test a new drug, felzartamab, for primary membranous nephropathy (PMN), a rare kidney disease affecting about 36,000 U.S. patients. 目前没有经核准的PMN治疗方法。 There are currently no approved treatments for PMN. Felzartamab是一种反CD38抗体,旨在减少有害的血浆细胞。 Felzartamab, an anti-CD38 antibody, aims to reduce harmful plasma cells. 这项研究将比较其有效性和塔克罗利穆斯的效力,预计将在2029年完成。 The study will compare its effectiveness to tacrolimus and is expected to conclude in 2029.